Apixaban
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Deep Vein Thrombosis
Conditions
Deep Vein Thrombosis
Trial Timeline
Feb 19, 2019 → Jun 3, 2019
NCT ID
NCT03590743About Apixaban
Apixaban is a approved stage product being developed by Pfizer for Deep Vein Thrombosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03590743. Target conditions include Deep Vein Thrombosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04681482 | Pre-clinical | Completed |
| NCT03590743 | Approved | Terminated |
| NCT02369653 | Phase 3 | Completed |
| NCT01884337 | Approved | Completed |
| NCT01707394 | Phase 1 | Completed |
| NCT02034591 | Phase 1 | Completed |
| NCT01195727 | Phase 1 | Terminated |
| NCT02034578 | Phase 1 | Completed |
| NCT02034565 | Phase 1 | Completed |
Competing Products
20 competing products in Deep Vein Thrombosis